Invitrogen Closes $210M Sale of BioReliance to Avista Capital | GenomeWeb
NEW YORK (GenomeWeb News) - Invitrogen has closed the $210 million sale of its BioReliance unit to Avista Capital Partners as part of its plans to better organize some of its acquisitions and streamline its focus, the company said today.
 
As GenomeWeb Daily News reported on Feb. 14, Invitrogen’s CEO and chairman Greg Lucier agreed to sell the biological services unit to Avista in an effort to focus on its platform of scientific technologies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.